U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Pleural Malignant Mesothelioma

MedGen UID:
1661826
•Concept ID:
C4743579
•
Neoplastic Process

Definition

Malignant mesothelioma of the pleura that is not amenable to surgical resection. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUnresectable Pleural Malignant Mesothelioma

Professional guidelines

PubMed

Nivolumab for the treatment of unresectable pleural mesothelioma.
Hotta K, Fujimoto N, Kozuki T, Aoe K, Kiura K
Expert Opin Biol Ther 2020 Feb;20(2):109-114. Epub 2019 Dec 16 doi: 10.1080/14712598.2020.1703945. PMID: 31825692
Recent advances in the treatment of malignant pleural mesothelioma.
Ramalingam SS, Belani CP
J Thorac Oncol 2008 Sep;3(9):1056-64. doi: 10.1097/JTO.0b013e3181834f66. PMID: 18758312
Systemic chemotherapy in the management of malignant peritoneal mesothelioma.
Garcia-Carbonero R, Paz-Ares L
Eur J Surg Oncol 2006 Aug;32(6):676-81. Epub 2006 Apr 17 doi: 10.1016/j.ejso.2006.03.009. PMID: 16616827

Recent clinical studies

Etiology

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, Nowak AK, Fujimoto N, Tsao AS, Mansfield AS, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G
Ann Oncol 2022 May;33(5):488-499. Epub 2022 Feb 3 doi: 10.1016/j.annonc.2022.01.074. PMID: 35124183
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G
Lancet 2021 Jan 30;397(10272):375-386. Epub 2021 Jan 21 doi: 10.1016/S0140-6736(20)32714-8. PMID: 33485464
Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma.
Ghirardelli P, Franceschini D, D'Aveni A, Dominici L, Ravasio A, Marzo M, Villa E, Di Noia V, Scorsetti M, Vavassori V, Ceresoli GL
Lung Cancer 2021 Feb;152:1-6. Epub 2020 Nov 26 doi: 10.1016/j.lungcan.2020.11.022. PMID: 33310300
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230
Malignant pleural mesothelioma.
Hughes RS
Am J Med Sci 2005 Jan;329(1):29-44. doi: 10.1097/00000441-200501000-00007. PMID: 15654178

Diagnosis

Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe.
Moore A, Bennett B, Taylor-Stokes G, McDonald L, Daumont MJ
BMC Cancer 2022 Jun 23;22(1):693. doi: 10.1186/s12885-022-09750-7. PMID: 35739480Free PMC Article
Updates in the diagnosis and treatment of malignant pleural mesothelioma.
Katzman D, Sterman DH
Curr Opin Pulm Med 2018 Jul;24(4):319-326. doi: 10.1097/MCP.0000000000000489. PMID: 29553973
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230
Malignant pleural mesothelioma.
Tsao AS, Wistuba I, Roth JA, Kindler HL
J Clin Oncol 2009 Apr 20;27(12):2081-90. Epub 2009 Mar 2 doi: 10.1200/JCO.2008.19.8523. PMID: 19255316Free PMC Article
Malignant pleural mesothelioma.
Hughes RS
Am J Med Sci 2005 Jan;329(1):29-44. doi: 10.1097/00000441-200501000-00007. PMID: 15654178

Therapy

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, Nowak AK, Fujimoto N, Tsao AS, Mansfield AS, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G
Ann Oncol 2022 May;33(5):488-499. Epub 2022 Feb 3 doi: 10.1016/j.annonc.2022.01.074. PMID: 35124183
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
Tsao AS, Pass HI, Rimner A, Mansfield AS
J Clin Oncol 2022 Feb 20;40(6):681-692. Epub 2022 Jan 5 doi: 10.1200/JCO.21.01567. PMID: 34985934Free PMC Article
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G
Lancet 2021 Jan 30;397(10272):375-386. Epub 2021 Jan 21 doi: 10.1016/S0140-6736(20)32714-8. PMID: 33485464
Anti-CTLA-4 therapy for malignant mesothelioma.
Guazzelli A, Bakker E, Krstic-Demonacos M, Lisanti MP, Sotgia F, Mutti L
Immunotherapy 2017 Mar;9(3):273-280. doi: 10.2217/imt-2016-0123. PMID: 28231719
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230

Prognosis

New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
Tsao AS, Pass HI, Rimner A, Mansfield AS
J Clin Oncol 2022 Feb 20;40(6):681-692. Epub 2022 Jan 5 doi: 10.1200/JCO.21.01567. PMID: 34985934Free PMC Article
Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Cui W, Popat S
Drugs 2021 Jun;81(9):971-984. Epub 2021 Jun 9 doi: 10.1007/s40265-021-01506-0. PMID: 34106454
Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
Tsao A, Nakano T, Nowak AK, Popat S, Scagliotti GV, Heymach J
Semin Oncol 2019 Apr;46(2):145-154. Epub 2019 Jun 18 doi: 10.1053/j.seminoncol.2019.06.001. PMID: 31280996
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230
Malignant pleural mesothelioma.
Hughes RS
Am J Med Sci 2005 Jan;329(1):29-44. doi: 10.1097/00000441-200501000-00007. PMID: 15654178

Clinical prediction guides

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, Nowak AK, Fujimoto N, Tsao AS, Mansfield AS, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G
Ann Oncol 2022 May;33(5):488-499. Epub 2022 Feb 3 doi: 10.1016/j.annonc.2022.01.074. PMID: 35124183
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
Tsao AS, Pass HI, Rimner A, Mansfield AS
J Clin Oncol 2022 Feb 20;40(6):681-692. Epub 2022 Jan 5 doi: 10.1200/JCO.21.01567. PMID: 34985934Free PMC Article
Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Cui W, Popat S
Drugs 2021 Jun;81(9):971-984. Epub 2021 Jun 9 doi: 10.1007/s40265-021-01506-0. PMID: 34106454
Updates in the diagnosis and treatment of malignant pleural mesothelioma.
Katzman D, Sterman DH
Curr Opin Pulm Med 2018 Jul;24(4):319-326. doi: 10.1097/MCP.0000000000000489. PMID: 29553973
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230

Recent systematic reviews

Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
Green J, Dundar Y, Dodd S, Dickson R, Walley T
Cochrane Database Syst Rev 2007 Jan 24;2007(1):CD005574. doi: 10.1002/14651858.CD005574.pub2. PMID: 17253564Free PMC Article
Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
Dundar Y, Bagust A, Dickson R, Dodd S, Green J, Haycox A, Hill R, McLeod C, Walley T
Health Technol Assess 2007 Jan;11(1):1-90. doi: 10.3310/hta11010. PMID: 17181984
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, Meert AP, Sculier JP
Lung Cancer 2002 Nov;38(2):111-21. doi: 10.1016/s0169-5002(02)00180-0. PMID: 12399121

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...